Business Context and Reporting Period
This Form 6-K filing is submitted by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) on September 20, 2021, regarding a press release issued on September 17, 2021. The registrant is a foreign private issuer incorporated in Belgium, headquartered in Mechelen.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves solely to incorporate a press release by reference and does not contain a financial statement or quantitative data table.
Material Changes
No material financial changes versus prior periods are detailed in this specific filing text. The document references a press release (Exhibit 99.1) containing a quote from Dr. Walid Abi-Saab, but the content of that release is not included in the provided text.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or a discussion of risks and contingencies within the body text provided. It notes that the press release is incorporated into various Registration Statements (Forms F-3 and S-8).
Investor Verification Checklist
- Verify the actual content of the September 17, 2021 press release (Exhibit 99.1) to understand the material event triggering this filing.
- Confirm the identity of the registrant as Galapagos NV, noting the discrepancy with the "Lakefront Biotherapeutics NV" metadata.
- Review the referenced Registration Statements (File Nos. 333-230639 and various S-8 filings) for context on the incorporated information.
- Check for subsequent filings if the press release contained forward-looking statements requiring updates.